Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458935 | 0.86 | NPSR1 (0.47) | NPSR1ALDH1A1ATMTDP1L3MBTL1 | |
| SCHEMBL6905225 | 0.83 | KMT2A (0.46) | NPSR1ALDH1A1ATMTDP1L3MBTL1 | |
| SCHEMBL3424139 | 0.81 | SMN1; SMN2 (0.44) | NPSR1ALDH1A1ATMTDP1L3MBTL1 | |
| SCHEMBL5141689 | 0.80 | NPSR1 (0.46) | NPSR1ALDH1A1ATMTDP1L3MBTL1 | |
| SCHEMBL402771 | 0.80 | NPSR1 (0.41) | NPSR1ALDH1A1ATMTDP1L3MBTL1 | |
| SCHEMBL400582 | 0.79 | NPSR1 (0.44) | NPSR1ALDH1A1ATMTDP1L3MBTL1 | |
| SCHEMBL10912480 | 0.77 | NPSR1 (0.41) | NPSR1ALDH1A1ATMTDP1L3MBTL1 | |
| SCHEMBL75883 | 0.77 | NPSR1 (0.64) | NPSR1ALDH1A1ATMTDP1L3MBTL1 | |
| SCHEMBL75885 | 0.77 | NPSR1 (0.64) | NPSR1ALDH1A1ATMTDP1L3MBTL1 | |
| SCHEMBL28148401 | 0.77 | NPSR1 (0.64) | NPSR1ALDH1A1ATMTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292189-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC | 2019-09-26 | — | — | US | disclosed |
| CN-109476669-A | Lim kinase inhibitor | 富荣吉有限责任公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2017201187-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC (US) | 2017-11-23 | — | — | WO | disclosed |
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8101773-B2 | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2134677-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL)PHENYL]-1H-PYRAZOL-5-YL}CARBAMOYL)-AMINO]-3-CHLOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2111401-B1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20100150863-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| CN-101679362-A | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cance | BAYER PHARMACEUTICALS CORP | 2010-03-24 | — | — | CN | disclosed |
| US-20100063107-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2134677-A2 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL)PHENYL]-1H-PYRAZOL-5-YL}CARBAMOYL)-AMINO]-3-CHLOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2111401-A1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1962830-A2 | AZAINDOLE INHIBITORS OF AURORA KINASES | SmithKline Beecham Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008079968-A1 | 4-{4-[({3-TERT-BUTYL-1-[3-(HYDROXYMETHYL) PHENYL]-1H-PYRAZOL-5-YL } CARBAMOYL)-AMINO] -3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS WELL AS PRODRUGS AND SALTS THEREOF FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079972-A2 | 4-{4- [ ({3-TERT-BUTYL-1- [3- (HYDROXYMETHYL) PHENYL] - 1H- PYRAZOL- 5 -YL } CARBAMOYL) -AMIN O] -3-CHLOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE AS AN INHIBITOR OF THE VEGFR KINASE FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007076348-A2 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063107-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUNDS USEFULL IN THE TREATMENT OF CANCER | TP53, DOT1L, VHL | NPSR1 4479/4885ALDH1A1 345/4885ATM 2450/4885 |
| US-20100150863-A1 | HYDROXY METHYL PHENYL PYRAZOLYL UREA COMPOUND USEFUL IN TREATMENT OF CANCER | TP53, MGMT, VHL | NPSR1 4492/4885ALDH1A1 983/4885ATM 867/4885 |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | MAP3K1, MAP3K3, MAP3K5 | NPSR1 3767/4885ALDH1A1 3244/4885ATM 555/4885 |
| US-20190292189-A1 | LIM KINASE INHIBITORS | LIMK1, LIMK2, LIMA1 | NPSR1 4409/4885ALDH1A1 4562/4885ATM 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.